Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884773 | 1.00 | KDM4E (0.33) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL6884355 | 0.80 | CNR2 (0.33) | KDM4EALDH1A1GAAMAPT | |
| SCHEMBL423043 | 0.80 | CNR2 (0.33) | KDM4EALDH1A1GAAMAPT | |
| SCHEMBL19439649 | 0.78 | CACNA1H (0.33) | KDM4E | |
| SCHEMBL28781603 | 0.72 | CA12 (0.47) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL955181 | 0.70 | TAAR1 (0.39) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL28117984 | 0.69 | PDE2A (0.42) | GAAPDE2A | |
| SCHEMBL320662 | 0.68 | L3MBTL1 (0.47) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL320663 | 0.68 | L3MBTL1 (0.47) | KDM4EALDH1A1GAAMAPTMEN1 | |
| SCHEMBL424780 | 0.68 | KIF11 (0.40) | GAAMEN1KMT2APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470498-B1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-02-11 | — | — | EP | disclosed |
| CN-102740848-B | Tetrahydro-pyran derivatives against neurological illnesses | HOFFMANN LA ROCHE | 2014-08-27 | — | — | CN | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8404673-B2 | Carbocyclic GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2531190-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| CN-102740848-A | Tetrahydro-pyran derivatives against neurological illnesses | HOFFMANN LA ROCHE | 2012-10-17 | — | — | CN | disclosed |
| EP-2470498-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120022042-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | KOLCZEWSKI SABINE (DE) | 2012-01-26 | — | — | US | disclosed |
| US-8080541-B2 | Carbocyclic GlyT-1 receptor antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| WO-2011095434-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011023667-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053904-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | KDM4E 4374/4885ALDH1A1 1488/4885GAA 1010/4885 |
| US-20120022042-A1 | CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS | GRIA1, GLRA1, GRIA3 | KDM4E 4374/4885ALDH1A1 1488/4885GAA 1010/4885 |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | GLRA1, GRIA1, GLRA2 | KDM4E 3657/4885ALDH1A1 1239/4885GAA 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.